MedPath

SYMPROIC

These highlights do not include all the information needed to use SYMPROIC safely and effectively. See full prescribing information for SYMPROIC. SYMPROIC (naldemedine tablets for oral use) Initial U.S. Approval: 2017

Approved
Approval ID

b1a1256c-a1eb-4abe-ab1e-30e4711afd16

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Dec 23, 2022

Manufacturers
FDA

BioDelivery Sciences International Inc

DUNS: 016058955

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

naldemedine

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code59385-041
Application NumberNDA208854
Product Classification
M
Marketing Category
C73594
G
Generic Name
naldemedine
Product Specifications
Route of AdministrationORAL
Effective DateJuly 30, 2021
FDA Product Classification

INGREDIENTS (7)

naldemedine tosylateActive
Quantity: 0.2 mg in 1 1
Code: V1N8F1RVVO
Classification: ACTIM
Magnesium StearateInactive
Code: 70097M6I30
Classification: IACT
Ferric Oxide YellowInactive
Code: EX438O2MRT
Classification: IACT
MannitolInactive
Code: 3OWL53L36A
Classification: IACT
Croscarmellose SodiumInactive
Code: M28OL1HH48
Classification: IACT
Hypromellose, UnspecifiedInactive
Code: 3NXW29V3WO
Classification: IACT
TalcInactive
Code: 7SEV7J4R1U
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SYMPROIC - FDA Drug Approval Details